Display Settings:

Format

Send to:

Choose Destination
    Immunol Res. 2008;42(1-3):233-45.

    Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.

    Source

    Department of Microbiology, University of Pennsylvania School of Medicine, 323 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA, 19104-6076, USA.

    Abstract

    Our laboratory is interested in how immunogenicity may be modulated in vivo in order to better design more effective immunotherapeutics against cancer. Our main approach is to use a facultative intracellular bacterium, Listeria monocytogenes, which has the unusual ability to live and grow in the cytoplasm of the cell and is thus an excellent vector for targeting passenger antigens to the major histocompatibility complex (MHC) class I pathway of antigen processing with the generation of authentic CTL epitopes. We have used this approach to target tumor antigens expressed on breast, melanoma and cervical cancer. We are also exploring the role of Listerial virulence factors in potentiating adaptive immune responses by activating innate immunity. Specifically, we are using these proteins as adjuvants for B cell lymphomas.

    PMID:
    19018479
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2763613
    Free PMC Article

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk